|
Nikhil Thatte
Principal
Lumira Ventures
|
Nikhil joined Lumira Ventures in March 2019. Having spent his entire career in the healthcare industry, Nikhil is passionate about using his broad expertise to help inventors and entrepreneurs bring clinically meaningful treatments to patients in need. As Principal, Nikhil’s day-to-day tasks include new deal sourcing, investment due diligence and supporting Lumira’s portfolio companies. Nikhil is primarily focused on next generation modalities including cell and gene therapy, gene editing, and protein degradation. Nikhil currently serves as a board observer at XyloCor Therapeutics based in Philadelphia.
Prior to Lumira Capital, Nikhil worked as a Director with DRI Capital, a pioneer in royalty monetization solutions, where he managed relationships with inventors, academics and companies, and supported in the investment due diligence process. Prior to DRI Capital, Nikhil was a Consultant with ZS Associates, a global marketing and sales consulting firm where he provided expertise to over 20 pharmaceutical and biotechnology clients across a broad range of projects and therapeutic areas. He also served as an Analyst with Bayer AG and Health Canada.
Nikhil holds a Bachelor’s Degree in Chemical Engineering from McGill University
Prior to Lumira Capital, Nikhil worked as a Director with DRI Capital, a pioneer in royalty monetization solutions, where he managed relationships with inventors, academics and companies, and supported in the investment due diligence process. Prior to DRI Capital, Nikhil was a Consultant with ZS Associates, a global marketing and sales consulting firm where he provided expertise to over 20 pharmaceutical and biotechnology clients across a broad range of projects and therapeutic areas. He also served as an Analyst with Bayer AG and Health Canada.
Nikhil holds a Bachelor’s Degree in Chemical Engineering from McGill University